<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36450833</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>19</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-5462</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>5</Issue><PubDate><Year>2023</Year><Month>May</Month></PubDate></JournalIssue><Title>Gene therapy</Title><ISOAbbreviation>Gene Ther</ISOAbbreviation></Journal><ArticleTitle>In vivo genome editing using novel AAV-PHP variants rescues motor function deficits and extends survival in a SOD1-ALS mouse model.</ArticleTitle><Pagination><StartPage>443</StartPage><EndPage>454</EndPage><MedlinePgn>443-454</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41434-022-00375-w</ELocationID><Abstract><AbstractText>CRISPR-based gene editing technology represents a promising approach to deliver therapies for inherited disorders, including amyotrophic lateral sclerosis (ALS). Toxic gain-of-function superoxide dismutase 1 (SOD1) mutations are responsible for ~20% of familial ALS cases. Thus, current clinical strategies to treat SOD1-ALS are designed to lower SOD1 levels. Here, we utilized AAV-PHP.B variants to deliver CRISPR-Cas9 guide RNAs designed to disrupt the human SOD1 (huSOD1) transgene in SOD1<sup>G93A</sup> mice. A one-time intracerebroventricular injection of AAV.PHP.B-huSOD1-sgRNA into neonatal H11<sup>Cas9</sup> SOD1<sup>G93A</sup> mice caused robust and sustained mutant huSOD1 protein reduction in the cortex and spinal cord, and restored motor function. Neonatal treatment also reduced spinal motor neuron loss, denervation at neuromuscular junction (NMJ) and muscle atrophy, diminished axonal damage and preserved compound muscle action potential throughout the lifespan of treated mice. SOD1<sup>G93A</sup> treated mice achieved significant disease-free survival, extending lifespan by more than 110 days. Importantly, a one-time intrathecal or intravenous injection of AAV.PHP.eB-huSOD1-sgRNA in adult H11<sup>Cas9</sup> SOD1<sup>G93A</sup> mice, immediately before symptom onset, also extended lifespan by at least 170 days. We observed substantial protection against disease progression, demonstrating the utility of our CRISPR editing preclinical approach for target evaluation. Our approach uncovered key parameters (e.g., AAV capsid, Cas9 expression) that resulted in improved efficacy compared to similar approaches and can also serve to accelerate drug target validation.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s), under exclusive licence to Springer Nature Limited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yi A</ForeName><Initials>YA</Initials><AffiliationInfo><Affiliation>Biogen Inc., Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kankel</LastName><ForeName>Mark W</ForeName><Initials>MW</Initials><AffiliationInfo><Affiliation>Apple Tree Partners (ATP) Research &amp; Development, Branford, CT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hana</LastName><ForeName>Sam</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-0847-7159</Identifier><AffiliationInfo><Affiliation>Biogen Inc., Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lau</LastName><ForeName>Shukkwan Kelly</ForeName><Initials>SK</Initials><AffiliationInfo><Affiliation>Biogen Inc., Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zavodszky</LastName><ForeName>Maria I</ForeName><Initials>MI</Initials><AffiliationInfo><Affiliation>Biogen Inc., Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McKissick</LastName><ForeName>Olivia</ForeName><Initials>O</Initials><Identifier Source="ORCID">0000-0002-1733-2971</Identifier><AffiliationInfo><Affiliation>Biogen Inc., Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mastrangelo</LastName><ForeName>Nicole</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Biogen Inc., Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dion</LastName><ForeName>Jessica</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Biogen Inc., Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Bin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Biogen Inc., Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferretti</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Biogen Inc., Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koske</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Biogen Inc., Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lehman</LastName><ForeName>Sydney</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Biogen Inc., Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koszka</LastName><ForeName>Kathryn</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Biogen Inc., Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McLaughlin</LastName><ForeName>Helen</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Biogen Inc., Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Mei</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Biogen Inc., Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marshall</LastName><ForeName>Eric</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Biogen Inc., Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fabian</LastName><ForeName>Attila J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Biogen Inc., Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cullen</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Biogen Inc., Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marsh</LastName><ForeName>Galina</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Biogen Inc., Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hamann</LastName><ForeName>Stefan</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-0983-2589</Identifier><AffiliationInfo><Affiliation>Biogen Inc., Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Craft</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Biogen Inc., Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sebalusky</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Biogen Inc., Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arnold</LastName><ForeName>H Moore</ForeName><Initials>HM</Initials><AffiliationInfo><Affiliation>Biogen Inc., Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Driscoll</LastName><ForeName>Rachelle</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Biogen Inc., Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sheehy</LastName><ForeName>Adam</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-0080-8950</Identifier><AffiliationInfo><Affiliation>Biogen Inc., Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luo</LastName><ForeName>Yi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Biogen Inc., Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manca</LastName><ForeName>Sonia</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-4974-6148</Identifier><AffiliationInfo><Affiliation>Biogen Inc., Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carlile</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Biogen Inc., Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Chao</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Biogen Inc., Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sigrist</LastName><ForeName>Kirsten</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-7342-5750</Identifier><AffiliationInfo><Affiliation>Biogen Inc., Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McCampbell</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Biogen Inc., Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Henderson</LastName><ForeName>Christopher E</ForeName><Initials>CE</Initials><AffiliationInfo><Affiliation>Biogen Inc., Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lo</LastName><ForeName>Shih-Ching</ForeName><Initials>SC</Initials><Identifier Source="ORCID">0000-0002-5187-0730</Identifier><AffiliationInfo><Affiliation>Biogen Inc., Cambridge, MA, USA. joyce.lo@biogen.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Gene Ther</MedlineTA><NlmUniqueID>9421525</NlmUniqueID><ISSNLinking>0969-7128</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D013482">Superoxide Dismutase</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000606290">SOD1 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072669" MajorTopicYN="N">Gene Editing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013482" MajorTopicYN="N">Superoxide Dismutase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors would like to declare they are/were employees of Biogen Inc.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>1</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>11</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>10</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>19</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>12</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>30</Day><Hour>23</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36450833</ArticleId><ArticleId IdType="pmc">PMC9713118</ArticleId><ArticleId IdType="doi">10.1038/s41434-022-00375-w</ArticleId><ArticleId IdType="pii">10.1038/s41434-022-00375-w</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brown RH, Al-Chalabi A. Amyotrophic lateral Sclerosis. N Engl J Med. 2017;377:162&#x2013;72. doi: 10.1056/NEJMra1603471.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1603471</ArticleId><ArticleId IdType="pubmed">28700839</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen DR. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993;364:362. doi: 10.1038/364362c0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/364362c0</ArticleId><ArticleId IdType="pubmed">8332197</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen PM, Nilsson P, Keranen ML, Forsgren L, Hagglund J, Karlsborg M, et al. Phenotypic heterogeneity in motor neuron disease patients with CuZn-superoxide dismutase mutations in Scandinavia. Brain. 1997;120:1723&#x2013;37. doi: 10.1093/brain/120.10.1723.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/120.10.1723</ArticleId><ArticleId IdType="pubmed">9365366</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruijn LI, Cleveland DW. Mechanisms of selective motor neuron death in ALS: insights from transgenic mouse models of motor neuron disease. Neuropathol Appl Neurobiol. 1996;22:373&#x2013;87. doi: 10.1111/j.1365-2990.1996.tb00907.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2990.1996.tb00907.x</ArticleId><ArticleId IdType="pubmed">8930947</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer LR, Glass JD. Oxidative stress induced by loss of Cu,Zn-superoxide dismutase (SOD1) or superoxide-generating herbicides causes axonal degeneration in mouse DRG cultures. Acta Neuropathol. 2010;119:249&#x2013;59. doi: 10.1007/s00401-009-0631-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-009-0631-z</ArticleId><ArticleId IdType="pmc">PMC4334446</ArticleId><ArticleId IdType="pubmed">20039174</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurney ME, Pu H, Chiu AY, Canto MCD, Polchow CY, Alexander DD, et al. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science. 1994;264:1772&#x2013;5. doi: 10.1126/science.8209258.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.8209258</ArticleId><ArticleId IdType="pubmed">8209258</ArticleId></ArticleIdList></Reference><Reference><Citation>Ratovitski T, Corson LB, Strain J, Wong P, Cleveland DW, Culotta VC, et al. Variation in the biochemical/biophysical properties of mutant superoxide dismutase 1 enzymes and the rate of disease progression in familial amyotrophic lateral sclerosis kindreds. Hum Mol Genet. 1999;8:1451&#x2013;60. doi: 10.1093/hmg/8.8.1451.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/8.8.1451</ArticleId><ArticleId IdType="pubmed">10400992</ArticleId></ArticleIdList></Reference><Reference><Citation>Reaume AG, Elliott JL, Hoffman EK, Kowall NW, Ferrante RJ, Siwek DF, et al. Motor neurons in Cu/Zn superoxide dismutase-deficient mice develop normally but exhibit enhanced cell death after axonal injury. Nat Genet. 1996;13:43&#x2013;7. doi: 10.1038/ng0596-43.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng0596-43</ArticleId><ArticleId IdType="pubmed">8673102</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothstein JD. Current hypotheses for the underlying biology of amyotrophic lateral sclerosis. Ann Neurol. 2009;65:S3&#x2013;9. doi: 10.1002/ana.21543.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21543</ArticleId><ArticleId IdType="pubmed">19191304</ArticleId></ArticleIdList></Reference><Reference><Citation>Saccon RA, Bunton-Stasyshyn RK, Fisher EM, Fratta P. Is SOD1 loss of function involved in amyotrophic lateral sclerosis? Brain. 2013;136:2342&#x2013;58. doi: 10.1093/brain/awt097.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awt097</ArticleId><ArticleId IdType="pmc">PMC3722346</ArticleId><ArticleId IdType="pubmed">23687121</ArticleId></ArticleIdList></Reference><Reference><Citation>Bravo-Hernandez M, Tadokoro T, Navarro MR, Platoshyn O, Kobayashi Y, Marsala S, et al. Spinal subpial delivery of AAV9 enables widespread gene silencing and blocks motoneuron degeneration in ALS. Nat Med. 2020;26:118&#x2013;30. doi: 10.1038/s41591-019-0674-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-019-0674-1</ArticleId><ArticleId IdType="pmc">PMC8171115</ArticleId><ArticleId IdType="pubmed">31873312</ArticleId></ArticleIdList></Reference><Reference><Citation>McCampbell A, Cole T, Wegener AJ, Tomassy GS, Setnicka A, Farley BJ, et al. Antisense oligonucleotides extend survival and reverse decrement in muscle response in ALS models. J Clin Invest. 2018;128:3558&#x2013;67. doi: 10.1172/JCI99081.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI99081</ArticleId><ArticleId IdType="pmc">PMC6063493</ArticleId><ArticleId IdType="pubmed">30010620</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller T, Cudkowicz M, Shaw PJ, Andersen PM, Atassi N, Bucelli RC, et al. Phase 1&#x2013;2 trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. N Engl J Med. 2020;383:109&#x2013;19. doi: 10.1056/NEJMoa2003715.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2003715</ArticleId><ArticleId IdType="pubmed">32640130</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller T, Cudkowicz M on behalf of the VWG. Results from the Phase 3 VALOR study and its open-label extension: evaluating the clinical efficacy and safety of Tofersen in adults with ALS and confirmed SOD1 mutation. Am Neurol Assoc Annu Meet. 2021.</Citation></Reference><Reference><Citation>Broekman ML, Comer LA, Hyman BT, Sena-Esteves M. Adeno-associated virus vectors serotyped with AAV8 capsid are more efficient than AAV-1 or -2 serotypes for widespread gene delivery to the neonatal mouse brain. Neuroscience. 2006;138:501&#x2013;10. doi: 10.1016/j.neuroscience.2005.11.057.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2005.11.057</ArticleId><ArticleId IdType="pubmed">16414198</ArticleId></ArticleIdList></Reference><Reference><Citation>McLean JR, Smith GA, Rocha EM, Hayes MA, Beagan JA, Hallett PJ, et al. Widespread neuron-specific transgene expression in brain and spinal cord following synapsin promoter-driven AAV9 neonatal intracerebroventricular injection. Neurosci Lett. 2014;576:73&#x2013;8. doi: 10.1016/j.neulet.2014.05.044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2014.05.044</ArticleId><ArticleId IdType="pubmed">24882721</ArticleId></ArticleIdList></Reference><Reference><Citation>Borel F, Gernoux G, Sun H, Stock R, Blackwood M, Brown RH, et al. Safe and effective superoxide dismutase 1 silencing using artificial microRNA in macaques. Sci Transl Med. 2018;10:1&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">30381409</ArticleId></ArticleIdList></Reference><Reference><Citation>Dirren E, Aebischer J, Rochat C, Towne C, Schneider BL, Aebischer P. SOD1 silencing in motoneurons or glia rescues neuromuscular function in ALS mice. Ann Clin Transl Neurol. 2015;2:167&#x2013;84. doi: 10.1002/acn3.162.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.162</ArticleId><ArticleId IdType="pmc">PMC4338957</ArticleId><ArticleId IdType="pubmed">25750921</ArticleId></ArticleIdList></Reference><Reference><Citation>Iannitti T, Scarrott JM, Likhite S, Coldicott IRP, Lewis KE, Heath PR, et al. Translating SOD1 Gene Silencing toward the Clinic: A Highly Efficacious, Off-Target-free, and Biomarker-Supported Strategy for fALS. Mol Ther - Nucleic Acids. 2018;12:75&#x2013;88. doi: 10.1016/j.omtn.2018.04.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.omtn.2018.04.015</ArticleId><ArticleId IdType="pmc">PMC6023790</ArticleId><ArticleId IdType="pubmed">30195799</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoica L, Todeasa SH, Cabrera GT, Salameh JS, Elmallah MK, Mueller C, et al. Adeno-associated virus-delivered artificial microRNA extends survival and delays paralysis in an amyotrophic lateral sclerosis mouse model. Ann Neurol. 2016;79:687&#x2013;700. doi: 10.1002/ana.24618.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24618</ArticleId><ArticleId IdType="pmc">PMC5374859</ArticleId><ArticleId IdType="pubmed">26891182</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H, Yang B, Qiu L, Yang C, Kramer J, Su Q, et al. Widespread spinal cord transduction by intrathecal injection of rAAV delivers efficacious RNAi therapy for amyotrophic lateral sclerosis. Hum Mol Genet. 2014;23:668&#x2013;81. doi: 10.1093/hmg/ddt454.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddt454</ArticleId><ArticleId IdType="pmc">PMC3888258</ArticleId><ArticleId IdType="pubmed">24108104</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho SW, Kim S, Kim JM, Kim JS. Targeted genome engineering in human cells with the Cas9 RNA-guided endonuclease. Nat Biotechnol. 2013;31:230&#x2013;2. doi: 10.1038/nbt.2507.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.2507</ArticleId><ArticleId IdType="pubmed">23360966</ArticleId></ArticleIdList></Reference><Reference><Citation>Jinek M, East A, Cheng A, Lin S, Ma E, Doudna J. RNA-programmed genome editing in human cells. Elife. 2013;2:e00471. doi: 10.7554/eLife.00471.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.00471</ArticleId><ArticleId IdType="pmc">PMC3557905</ArticleId><ArticleId IdType="pubmed">23386978</ArticleId></ArticleIdList></Reference><Reference><Citation>Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, et al. Multiplex genome engineering using CRISPR/Cas systems. Science. 2013;339:819&#x2013;23. doi: 10.1126/science.1231143.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1231143</ArticleId><ArticleId IdType="pmc">PMC3795411</ArticleId><ArticleId IdType="pubmed">23287718</ArticleId></ArticleIdList></Reference><Reference><Citation>Mali P, Yang L, Esvelt KM, Aach J, Guell M, DiCarlo JE, et al. RNA-guided human genome engineering via Cas9. Science. 2013;339:823&#x2013;7. doi: 10.1126/science.1232033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1232033</ArticleId><ArticleId IdType="pmc">PMC3712628</ArticleId><ArticleId IdType="pubmed">23287722</ArticleId></ArticleIdList></Reference><Reference><Citation>Platt RJJ, Chen S, Zhou Y, Yim MJJ, Swiech L, Kempton HRR, et al. CRISPR-Cas9 knockin mice for genome editing and cancer modeling. Cell. 2014;159:440&#x2013;55. doi: 10.1016/j.cell.2014.09.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2014.09.014</ArticleId><ArticleId IdType="pmc">PMC4265475</ArticleId><ArticleId IdType="pubmed">25263330</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang D, Zhang F, Gao G. CRISPR-based therapeutic genome editing: strategies and in vivo delivery by AAV vectors. Cell. 2020;181:136&#x2013;50. doi: 10.1016/j.cell.2020.03.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.03.023</ArticleId><ArticleId IdType="pmc">PMC7236621</ArticleId><ArticleId IdType="pubmed">32243786</ArticleId></ArticleIdList></Reference><Reference><Citation>Santiago Y, Chan E, Liu PQ, Orlando S, Zhang L, Urnov FD, et al. Targeted gene knockout in mammalian cells by using engineered zinc-finger nucleases. Proc Natl Acad Sci USA. 2008;105:5809&#x2013;14. doi: 10.1073/pnas.0800940105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0800940105</ArticleId><ArticleId IdType="pmc">PMC2299223</ArticleId><ArticleId IdType="pubmed">18359850</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaj T, Ojala DS, Ekman FK, Byrne LC, Limsirichai P, Schaffer DV. In vivo genome editing improves motor function and extends survival in a mouse model of ALS. Sci Adv. 2017;3:1&#x2013;11. doi: 10.1126/sciadv.aar3952.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.aar3952</ArticleId><ArticleId IdType="pmc">PMC5738228</ArticleId><ArticleId IdType="pubmed">29279867</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim CKW, Gapinske M, Brooks AK, Woods WS, Powell JE, Zeballos CM, et al. Treatment of a mouse model of ALS by in vivo base editing. Mol Ther. 2020;28:1177&#x2013;89. doi: 10.1016/j.ymthe.2020.01.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2020.01.005</ArticleId><ArticleId IdType="pmc">PMC7132599</ArticleId><ArticleId IdType="pubmed">31991108</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan KY, Jang MJ, Yoo BB, Greenbaum A, Ravi N, Wu WLL, et al. Engineered AAVs for Efficient Noninvasive gene delivery to the central and peripheral nervous systems. Nat Neurosci. 2017;20:1172&#x2013;9. doi: 10.1038/nn.4593.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn.4593</ArticleId><ArticleId IdType="pmc">PMC5529245</ArticleId><ArticleId IdType="pubmed">28671695</ArticleId></ArticleIdList></Reference><Reference><Citation>Deverman BE, Pravdo PL, Simpson BP, Kumar SR, Chan KY, Banerjee A, et al. Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain. Nat Biotechnol. 2016;34:204&#x2013;9. doi: 10.1038/nbt.3440.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.3440</ArticleId><ArticleId IdType="pmc">PMC5088052</ArticleId><ArticleId IdType="pubmed">26829320</ArticleId></ArticleIdList></Reference><Reference><Citation>Hana S, Peterson M, McLaughlin H, Marshall E, Fabian AJ, McKissick O, et al. Highly efficient neuronal gene knockout in vivo by CRISPR-Cas9 via neonatal intracerebroventricular injection of AAV in mice. Gene Ther. 2021;28:646&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8599009</ArticleId><ArticleId IdType="pubmed">33558692</ArticleId></ArticleIdList></Reference><Reference><Citation>Torregrosa T, Lehman S, Hana S, Marsh G, Xu S, Koszka K, et al. Use of CRISPR/Cas9-mediated disruption of CNS cell type genes to profile transduction of AAV by neonatal intracerebroventricular delivery in mice. Gene Ther. 2021;28:456&#x2013;68. doi: 10.1038/s41434-021-00223-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41434-021-00223-3</ArticleId><ArticleId IdType="pmc">PMC8376643</ArticleId><ArticleId IdType="pubmed">33612827</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiou SH, Winters IP, Wang J, Naranjo S, Dudgeon C, Tamburini FB, et al. Pancreatic cancer modeling using retrograde viral vector delivery and in vivo CRISPR/Cas9-mediated somatic genome editing. Genes Dev. 2015;29:1576&#x2013;85. doi: 10.1101/gad.264861.115.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gad.264861.115</ArticleId><ArticleId IdType="pmc">PMC4526740</ArticleId><ArticleId IdType="pubmed">26178787</ArticleId></ArticleIdList></Reference><Reference><Citation>Rowland LP. How amyotrophic lateral sclerosis got its name the clinical-pathologic genius of Jean-Martin Charcot. Arch Neurol. 2001;58:512&#x2013;5. doi: 10.1001/archneur.58.3.512.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.58.3.512</ArticleId><ArticleId IdType="pubmed">11255459</ArticleId></ArticleIdList></Reference><Reference><Citation>Doench JG, Fusi N, Sullender M, Hegde M, Vaimberg EW, Donovan KF, et al. Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9. Nat Biotechnol. 2016;34:184&#x2013;91. doi: 10.1038/nbt.3437.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.3437</ArticleId><ArticleId IdType="pmc">PMC4744125</ArticleId><ArticleId IdType="pubmed">26780180</ArticleId></ArticleIdList></Reference><Reference><Citation>Doench JG, Hartenian E, Graham DB, Tothova Z, Hegde M, Smith I, et al. Rational design of highly active sgRNAs for CRISPR-Cas9-mediated gene inactivation. Nat Biotechnol. 2014;32:1262&#x2013;7. doi: 10.1038/nbt.3026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.3026</ArticleId><ArticleId IdType="pmc">PMC4262738</ArticleId><ArticleId IdType="pubmed">25184501</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen B, Gilbert LA, Cimini BA, Schnitzbauer J, Zhang W, Li GW, et al. Dynamic imaging of genomic loci in living human cells by an optimized CRISPR/Cas system. Cell. 2013;155:1479&#x2013;91. doi: 10.1016/j.cell.2013.12.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2013.12.001</ArticleId><ArticleId IdType="pmc">PMC3918502</ArticleId><ArticleId IdType="pubmed">24360272</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton AE, Majounie E, Waite A, Sim&#xf3;n-S&#xe1;nchez J, Rollinson S, Gibbs JR, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011;72:257&#x2013;68. doi: 10.1016/j.neuron.2011.09.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.09.010</ArticleId><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>Frankish A, Diekhans M, Ferreira AM, Johnson R, Jungreis I, Loveland J, et al. GENCODE reference annotation for the human and mouse genomes. Nucleic Acids Res. 2019;47:D766&#x2013;73. doi: 10.1093/nar/gky955.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gky955</ArticleId><ArticleId IdType="pmc">PMC6323946</ArticleId><ArticleId IdType="pubmed">30357393</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobin A, Gingeras TR Optimizing RNA-Seq Mapping with STAR. In: Carugo O, Eisenhaber F, editors. Data Mining Techniques for the Life Sciences. New York, NY: Springer; 2016 [cited 2022 Aug 23]. 245&#x2013;62. (Methods in Molecular Biology). 10.1007/978-1-4939-3572-7_13.</Citation><ArticleIdList><ArticleId IdType="pubmed">27115637</ArticleId></ArticleIdList></Reference><Reference><Citation>Li B, Dewey CN. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinform. 2011;12:323. doi: 10.1186/1471-2105-12-323.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2105-12-323</ArticleId><ArticleId IdType="pmc">PMC3163565</ArticleId><ArticleId IdType="pubmed">21816040</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao S, Gordon W, Du S, Zhang C, He W, Xi L, et al. QuickMIRSeq: a pipeline for quick and accurate quantification of both known miRNAs and isomiRs by jointly processing multiple samples from microRNA sequencing. BMC Bioinform. 2017;18:180. doi: 10.1186/s12859-017-1601-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12859-017-1601-4</ArticleId><ArticleId IdType="pmc">PMC5359966</ArticleId><ArticleId IdType="pubmed">28320324</ArticleId></ArticleIdList></Reference><Reference><Citation>Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550. doi: 10.1186/s13059-014-0550-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13059-014-0550-8</ArticleId><ArticleId IdType="pmc">PMC4302049</ArticleId><ArticleId IdType="pubmed">25516281</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu A, Ibrahim JG, Love MI. Heavy-tailed prior distributions for sequence count data: removing the noise and preserving large differences. Bioinformatics. 2019;35:2084&#x2013;92. doi: 10.1093/bioinformatics/bty895.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/bty895</ArticleId><ArticleId IdType="pmc">PMC6581436</ArticleId><ArticleId IdType="pubmed">30395178</ArticleId></ArticleIdList></Reference><Reference><Citation>Vecchia LD, Maria BD, Marinou K, Sideri R, Lucini A, Porta A, et al. Cardiovascular neural regulation is impaired in amyotrophic lateral sclerosis patients. A study by spectral and complexity analysis of cardiovascular oscillations. Physiol Meas. 2015;36:659&#x2013;70. doi: 10.1088/0967-3334/36/4/659.</Citation><ArticleIdList><ArticleId IdType="doi">10.1088/0967-3334/36/4/659</ArticleId><ArticleId IdType="pubmed">25798998</ArticleId></ArticleIdList></Reference><Reference><Citation>Linden D, Diehl RR, Berlit P. Reduced baroreflex sensitivity and cardiorespiratory transfer in amyotrophic lateral sclerosis. Electroencephalogr Clin Neurophysiol Mot. Control. 1998;109:387&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">9851294</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka Y, Yamada M, Koumura A, Sakurai T, Hayashi Y, Kimura A, et al. Cardiac sympathetic function in the patients with amyotrophic lateral sclerosis: analysis using cardiac [123I] MIBG scintigraphy. J Neurol. 2013;260:2380&#x2013;6. doi: 10.1007/s00415-013-7005-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-013-7005-0</ArticleId><ArticleId IdType="pubmed">23784610</ArticleId></ArticleIdList></Reference><Reference><Citation>Duchen LW, Strich SJ, Falconer DS. Clinical and pathological studies of an hereditary neuropathy in mice (Dystonia musculorum) Brain. 1964;87:367&#x2013;78. doi: 10.1093/brain/87.2.367.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/87.2.367</ArticleId><ArticleId IdType="pubmed">14188280</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatzipetros T, Kidd JD, Moreno AJ, Thompson K, Gill A, Vieira FG. A quick phenotypic neurological scoring system for evaluating disease progression in the SOD1-G93A Mouse Model of ALS. J Vis Exp. 2015;104:1&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4692639</ArticleId><ArticleId IdType="pubmed">26485052</ArticleId></ArticleIdList></Reference><Reference><Citation>Mancuso R, Osta R, Navarro X. Presymptomatic electrophysiological tests predict clinical onset and survival in SOD1G93A ALS mice. Muscle Nerve. 2014;50:943&#x2013;9. doi: 10.1002/mus.24237.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.24237</ArticleId><ArticleId IdType="pubmed">24619579</ArticleId></ArticleIdList></Reference><Reference><Citation>Mancuso R, Santos-Nogueira E, Osta R, Navarro X. Electrophysiological analysis of a murine model of motoneuron disease. Clin Neurophysiol. 2011;122:1660&#x2013;70. doi: 10.1016/j.clinph.2011.01.045.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinph.2011.01.045</ArticleId><ArticleId IdType="pubmed">21354365</ArticleId></ArticleIdList></Reference><Reference><Citation>Schiaffino S, Reggiani C. Myosin isoforms in mammalian skeletal muscle. J Appl Physiol. 1994;77:493&#x2013;501. doi: 10.1152/jappl.1994.77.2.493.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/jappl.1994.77.2.493</ArticleId><ArticleId IdType="pubmed">8002492</ArticleId></ArticleIdList></Reference><Reference><Citation>Hegedus J, Putman CT, Tyreman N, Gordon T. Preferential motor unit loss in the SOD1G93A transgenic mouse model of amyotrophic lateral sclerosis. J Physiol. 2008;586:3337&#x2013;51. doi: 10.1113/jphysiol.2007.149286.</Citation><ArticleIdList><ArticleId IdType="doi">10.1113/jphysiol.2007.149286</ArticleId><ArticleId IdType="pmc">PMC2538809</ArticleId><ArticleId IdType="pubmed">18467368</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanning KC, Kaplan A, Henderson CE. Motor neuron diversity in development and disease. Annu Rev Neurosci. 2010;33:409&#x2013;40. doi: 10.1146/annurev.neuro.051508.135722.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.neuro.051508.135722</ArticleId><ArticleId IdType="pubmed">20367447</ArticleId></ArticleIdList></Reference><Reference><Citation>McCombe PA, Pfluger C, Singh P, Lim CYH, Airey C, Henderson RD. Serial measurements of phosphorylated neurofilament-heavy in the serum of subjects with amyotrophic lateral sclerosis. J Neurol Sci. 2015;353:122&#x2013;9. doi: 10.1016/j.jns.2015.04.032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2015.04.032</ArticleId><ArticleId IdType="pubmed">25958264</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinacker P, Feneberg E, Weishaupt J, Brettschneider J, Tumani H, Andersen PM, et al. Neurofilaments in the diagnosis of motoneuron diseases: a prospective study on 455 patients. J Neurol Neurosurg Psychiatry. 2016;87:12&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">26296871</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu CH, Petzold A, Kalmar B, Dick J, Malaspina A, Greensmith L. Plasma neurofilament heavy chain levels correlate to markers of late stage disease progression and treatment response in SOD1G93A Mice that Model ALS. PLoS ONE. 2012;7:e40998. doi: 10.1371/journal.pone.0040998.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0040998</ArticleId><ArticleId IdType="pmc">PMC3397981</ArticleId><ArticleId IdType="pubmed">22815892</ArticleId></ArticleIdList></Reference><Reference><Citation>Foust KD, Salazar DL, Likhite S, Ferraiuolo L, Ditsworth D, Ilieva H, et al. Therapeutic AAV9-mediated Suppression of Mutant SOD1 Slows Disease Progression and Extends Survival in Models of Inherited ALS. Mol Ther. 2013;21:2148&#x2013;59. doi: 10.1038/mt.2013.211.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mt.2013.211</ArticleId><ArticleId IdType="pmc">PMC3863799</ArticleId><ArticleId IdType="pubmed">24008656</ArticleId></ArticleIdList></Reference><Reference><Citation>Hordeaux J, Wang Q, Katz N, Buza EL, Bell P, Wilson JM. The Neurotropic Properties of AAV-PHP.B Are Limited to C57BL/6J Mice [Internet]. Vol. 26, Molecular Therapy. Cell Press; 2018. 664&#x2013;8. www.moleculartherapy.org.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5911151</ArticleId><ArticleId IdType="pubmed">29428298</ArticleId></ArticleIdList></Reference><Reference><Citation>Hordeaux J, Yuan Y, Clark PM, Wang Q, Martino RA, Sims JJ, et al. The GPI-linked protein LY6A drives AAV-PHP.B transport across the blood-brain barrier. Mol Ther. 2019;27:912&#x2013;21. doi: 10.1016/j.ymthe.2019.02.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymthe.2019.02.013</ArticleId><ArticleId IdType="pmc">PMC6520463</ArticleId><ArticleId IdType="pubmed">30819613</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Q, Chan KY, Tobey IG, Chan YA, Poterba T, Boutros CL, et al. Delivering genes across the blood-brain barrier: LY6A, a novel cellular receptor for AAV-PHP.B capsids. 2019 10.1371/journal.pone.0225206.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6855452</ArticleId><ArticleId IdType="pubmed">31725765</ArticleId></ArticleIdList></Reference><Reference><Citation>Challis RC, Kumar SR, Chan KY, Challis C, Beadle K, Jang MJ, et al. Systemic AAV vectors for widespread and targeted gene delivery in rodents. Nat Protoc. 2019;14:379&#x2013;414. doi: 10.1038/s41596-018-0097-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41596-018-0097-3</ArticleId><ArticleId IdType="pubmed">30626963</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng HX, Zhai H, Shi Y, Liu G, Lowry J, Liu B, et al. Efficacy and long-term safety of CRISPR/Cas9 genome editing in the SOD1-linked mouse models of ALS. Commun Biol. 2021;4:1&#x2013;11. doi: 10.1038/s42003-021-01942-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s42003-021-01942-4</ArticleId><ArticleId IdType="pmc">PMC7994668</ArticleId><ArticleId IdType="pubmed">33767386</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>